Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways

Min Li1,2, Xuxiao He1,2, Weixing Guo3

  • 1CAS Key Laboratory of Nutrition, Metabolism and Food Safety Research, Shanghai Institute of Nutrition and Health (SINH), Chinese Academy of Sciences (CAS), Shanghai, China.

Nature Cancer
|February 5, 2022
PubMed

Insights

Hepatic aldolase B (Aldob) suppresses liver cancer by inhibiting glucose-6-phosphate dehydrogenase (G6PD). Loss of Aldob promotes hepatocellular carcinogenesis (HCC), suggesting Aldob as a therapeutic target.

Area of Science:

  • Oncology
  • Metabolic pathways
  • Cancer biology

Background:

  • Metabolic reprogramming is crucial in cancer, but its role in hepatocellular carcinogenesis (HCC) is not fully understood.
  • Aldolase B (Aldob) function in HCC development requires further elucidation.

Purpose of the Study:

  • To investigate the role of hepatic aldolase B (Aldob) in hepatocellular carcinogenesis (HCC).
  • To identify the molecular mechanism by which Aldob influences HCC progression.
  • To explore potential therapeutic strategies targeting metabolic pathways in HCC.

Main Methods:

  • Analysis of Aldob and glucose-6-phosphate dehydrogenase (G6PD) levels in human HCC tumors.
  • Generation and analysis of Aldob knockout mouse models (global and liver-specific).
  • Pharmacological and genetic inhibition of G6PD in mouse models.
  • Biochemical assays to determine the interaction between Aldob, G6PD, and p53.

Main Results:

  • Decreased Aldob and increased G6PD expression in human HCC correlate with poor patient prognosis.
  • Aldob deficiency promotes HCC development in mice by enhancing G6PD activity and pentose phosphate pathway (PPP) metabolism.
  • G6PD inhibition suppresses HCC, while Aldob restoration attenuates tumorigenesis in knockout mice.
  • Aldob forms a complex with G6PD and p53, potentiating p53-mediated G6PD inhibition independently of Aldob's enzymatic activity.

Conclusions:

  • Loss of hepatic Aldob contributes to HCC through enhanced G6PD activity and PPP metabolism.
  • Aldob acts as a tumor suppressor in HCC by forming a complex that inhibits G6PD.
  • Targeting the Aldob-G6PD-p53 axis represents a potential therapeutic strategy for HCC.

Related Concept Videos

Other Glycolytic Pathways01:24

Other Glycolytic Pathways

The pentose phosphate pathway (PPP) operates in parallel with glycolysis, facilitating the metabolism of both pentoses and glucose. This pathway consists of two distinct phases: the oxidative and non-oxidative phases. While it does not directly generate ATP, the intermediates formed during the process can integrate into glycolysis, contributing to cellular energy metabolism when required.Oxidative Phase: NADPH ProductionThe oxidative phase of the pentose phosphate pathway is primarily...
287
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Base-Catalyzed Aldol Addition Reaction01:08

Base-Catalyzed Aldol Addition Reaction

As depicted in Figure 1, base-catalyzed aldol addition involves adding two carbonyl compounds in aqueous sodium hydroxide to form a β-hydroxy carbonyl compound.
3.7K
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
371
Glycolysis: Preparatory Phase01:21

Glycolysis: Preparatory Phase

In cellular metabolism (the complete breakdown of glucose to extract energy),  glycolysis is the first step. Glycolysis takes place in the cytoplasm of both prokaryotic and eukaryotic cells. Glucose enters heterotrophic cells in two ways. One method is through secondary active transport, where the transport takes place against the glucose concentration gradient. The other mechanism uses a group of integral proteins called GLUT proteins, also known as glucose transporter proteins. These...
14.7K